Search
Rituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalIt was originally approved by the U.S. … On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808].
Vitamin D
go.drugbank.com/drugs/DB11094ApprovedInvestigationalNutraceuticalVet approvedVitamin D3 and D2 require hydroxylation in order to become biologically active in the human body. … Since vitamin D can be endogenously synthesized in adequate amounts by most mammals exposed to sufficient quantities of sunlight, vitamin D functions like a hormone on vitamin D receptors to regulate calcium
Carbamazepine
go.drugbank.com/drugs/DB00564ApprovedInvestigationalIt was initially approved by the FDA in 1965.[A180301] Aside from the above uses, this drug is also given to control the symptoms of bipolar 1.
Nipocalimab
go.drugbank.com/drugs/DB16257ApprovedInvestigational[L64042] It is administered by intravenous infusion.[L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis.
Tafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigational[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.
Tranexamic acid
go.drugbank.com/drugs/DB00302ApprovedInvestigationalIt possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent. … [L31883] It was first patented in 1957[A230108] and received its initial US approval in 1986.[L31858]
Lonafarnib
go.drugbank.com/drugs/DB06448ApprovedInvestigational[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an
Mepolizumab
go.drugbank.com/drugs/DB06612ApprovedInvestigationalThe pathogenesis of eosinophilia is complex, but IL-5 is recognized as a key cytokine involved in the differentiation, recruitment, activation, and prolonged survival of eosinophils in peripheral tissue … Mepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline.
Emapalumab
go.drugbank.com/drugs/DB14724ApprovedInvestigationalEmapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. … [L4840] As well, emapalumab was given the status of PRIME by the EMA.[L4845]
Levobetaxolol
go.drugbank.com/drugs/DB09351ApprovedIt was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.